|Articles|October 8, 2021
- Pharmaceutical Executive-10-01-2021
- Volume 41
- Issue 10
Pharmaceutical Executive, October 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
Addressing Systemic Racism in Biopharmaalmost 5 years ago
Understanding the HCP: Patient-Level Data Proves Valuablealmost 5 years ago
Industry Game Changer: RWE Impacts on Drug Developmentalmost 5 years ago
Opposites Attractalmost 5 years ago
Defining the Chief Data Officeralmost 5 years ago
Leading Through Transitionalmost 5 years ago
Biotech Stocks Continue With Underperformancealmost 5 years ago
Could Time Be the Next New Element in Pharma Revenue?almost 5 years ago
Sharing the Science: Pharma’s Content Evolutionalmost 5 years ago
Data Science Calls for Shift in Executive Leadership MethodsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
4
When Drug Pricing Becomes Trade Policy
5